Even as it stumbles in the US in its journey to become the first-ever targeted therapy for COPD, Dupixent (dupilumab) has taken a step closer to Europe. Today the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave its imprimatur to Sanofi and Regeneron Pharmaceuticals, Inc.’s anti-inflammatory juggernaut for the lung disease, and approval could come swiftly.
Key Takeaways
- The European Committee for Medicinal Products for Human Use has granted a positive opinion to Dupixent in COPD as the FDA pushes back its decision.
The CHMP said that Dupixent could be used as an add-on treatment for uncontrolled COPD patients with high levels of...
